Tin tức & Cập nhật
Xem bài viết Tiêu hóa
Xem
Chỉ hiển thị Multimedia

Seladelpar delivers improvements in cholestatic biomarkers, pruritus in PBC patients
09 May 2026
bởiStephen Padilla
Treatment with seladelpar for up to 2 years improves cholestatic biomarkers and pruritus in patients with primary biliary cholangitis (PBC), with no serious safety concerns noted with long-term use, as shown by interim results of the ASSURE study.








